Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future oncology, 2011 - Taylor & Francis
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future Oncology, 2011 - hero.epa.gov
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future Oncology, 2011 - go.gale.com
Hepatocellular carcinoma (HCC), or liver cancer, with a mounting annual incidence of 4.9
per 100,000 persons, is the third most common cause of cancer death worldwide [1-3]. In …
per 100,000 persons, is the third most common cause of cancer death worldwide [1-3]. In …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future Oncology, 2011 - cir.nii.ac.jp
抄録< jats: p> Despite recent advances in the understanding of the biologic basis of
hepatocellular carcinoma (HCC) development, the clinical management of the disease …
hepatocellular carcinoma (HCC) development, the clinical management of the disease …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Q Zhou, VW Lui, W Yeo - Future Oncology (London, England), 2011 - europepmc.org
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future Oncology, 2011 - augusta.elsevierpure.com
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future Oncology, 2011 - search.proquest.com
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future Oncology, 2011 - hub.hku.hk
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future oncology (London …, 2011 - pubmed.ncbi.nlm.nih.gov
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …